title: Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents.
abstract: Owing to their central role in the initiation and regulation of antitumor immunity, dendritic cells (DCs) have been widely tested for use in cancer immunotherapy. Despite several encouraging clinical applications, existing DC-based immunotherapy efforts have yielded inconsistent results. Recent work has identified strategies that may allow for more potent DC-based vaccines, such as the combination with antitumor agents that have the potential to synergistically enhance DC functions. Selected cytotoxic agents may stimulate DCs either by directly promoting their maturation or through the induction of immunogenic tumor cell death. Moreover, they may support DC-induced adaptive immune responses by disrupting tumor-induced immunosuppressive mechanisms via selective depletion or inhibition of regulatory subsets, such as myeloid-derived suppressor cells and/or regulatory T cells (Tregs). Here, we summarize our current knowledge on the capacity of anticancer chemotherapeutics to modulate DC phenotype and functions and the results of ongoing clinical trials evaluating the use of DC-based immunotherapy in combination with chemotherapy in cancer patients.
authors.affiliation: 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic; Sotio a.s., Prague, Czech Republic.
authors.forename: I
authors.initials: I
authors.lastname: Truxova
authors.affiliation: Sotio a.s., Prague, Czech Republic.
authors.forename: M
authors.initials: M
authors.lastname: Hensler
authors.affiliation: 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
authors.forename: P
authors.initials: P
authors.lastname: Skapa
authors.affiliation: 3rd Faculty of Medicine and Faculty Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic.
authors.forename: M J
authors.initials: MJ
authors.lastname: Halaska
authors.affiliation: Faculty of Medicine and Faculty Hospital in Hradec Kralove, Charles University, Prague, Czech Republic.
authors.forename: J
authors.initials: J
authors.lastname: Laco
authors.affiliation: Faculty of Medicine and Faculty Hospital in Hradec Kralove, Charles University, Prague, Czech Republic.
authors.forename: A
authors.initials: A
authors.lastname: Ryska
authors.affiliation: 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic; Sotio a.s., Prague, Czech Republic.
authors.forename: R
authors.initials: R
authors.lastname: Spisek
authors.affiliation: 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic; Sotio a.s., Prague, Czech Republic. Electronic address: fucikova@sotio.com.
authors.forename: J
authors.initials: J
authors.lastname: Fucikova
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D014611:Vaccination
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines
keywords: Chemotherapy; Damage-associated molecular patterns; Dendritic cell; Immunogenic cell death; Immunotherapy